ChartRow logo
Data provided bySource: Twelve Data
CORT
$70.07+1.23%
as of close, Nov 17, 2026
☾ AH $70.07 +1.23%
PeersHALOALNYTWSTKRYSHLPCVX
Share this page

CORT — Corcept Therapeutics Incorporated price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in CORT be worth today? →
CORT returns: By year · By month · By week · Trailing

Price data

Price
$70.07
YTD price return
+101.35%
YTD total return
+101.35%
Market cap
7.7B
Enterprise value
7.3B
Shares outstanding
109.4M
52W low
$28.66
52W high
$126.38
From 52W high
-44.56%
From 52W low
+144.49%
52W range
42%$28.66–$126
Beta
0.45

Volume

Rel volume
0.89×
30D volume
1.1M
30D $ vol
96.4M

Insider trading

Insider net 1W
−$727K
Insider net 1M
−$3.6M
Insider net 3M
−$28.5M
Insider net 1Y
−$87.9M

Form 4 transactions by trade date, as filed; latest on file 2026-11-13.

Fundamentals

Sales (ttm)
963.6M
Sales/share
$8.81
EPS (ttm)
$1.39
FCF (ttm)
194.6M
FCF/share
$1.78
Book value/share
$7.62
Net margin
16.84%
ROE
19.47%
ROA
15.70%
Current ratio
3.00

Growth (CAGR, ttm) · 10Y

Sales
+30.04%+28.88%+22.26%+28.87%
Net income
+52.99%+21.09%+8.80%+43.12%
FCF
+19.18%+8.03%+4.97%+26.97%
Shares
+4.05%+2.02%-1.06%-0.14%

Per-share growth (CAGR, ttm) · 10Y

EPS
+57.24%+19.91%+10.91%+42.64%
Sales/share
+24.98%+26.34%+23.57%+29.29%
FCF/share
+14.54%+5.89%+6.10%+27.15%
Book value/share
+26.83%+19.36%+10.24%+39.08%
Price
-6.73%+39.31%+24.77%+22.17%
Total return
-6.73%+39.31%+24.77%+22.17%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
50.3×
P/OI (ttm)
69.1×
Fwd P/E
14.1×
P/S (ttm)
8.0×
P/B (mrq)
9.2×
P/FCF (ttm)
39.4×
EV/EBITDA (fy)
64.3×
EV/Sales (ttm)
7.6×
FCF yield (ttm)
2.54%
Buyback yield (realized, 1y)
-4.05%
Shareholder yield (realized, 1y)
-4.05%
Buyback yield (cash, ttm)
0.07%
Shareholder yield (cash, ttm)
0.07%

Vs own 10Y history

P/E
74th
P/OI
80th
P/S
69th
P/B
71st
P/FCF
75th

Bar = where today’s multiple sits in CORT’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
+1.23%
5D
-4.47%
1M
-36.39%
3M
-40.20%
YTD
+101.35%
1Y
-6.72%
5Y
+202.29%
1D
+1.23%
5D
-4.47%
1M
-36.39%
3M
-40.20%
YTD
+101.35%
1Y
-6.72%
5Y
+202.29%

Fundamentals#

Revenue

5Y CAGR +16.6%5Y CAGR +16.6%YoY +64.0%
$963.6M TTM$340.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR −19.0%10Y n/mYoY +1022.7%
$110.9M TTM$114.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR −0.7%10Y n/mYoY +531.3%
$1.39 TTM$1.01 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR −1.2%10Y CAGR +46.5%YoY +161.0%
$194.6M TTM$142.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow $198.1M, capex −$3.5M

Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Q3 2026: operating cash flow $142.9M, capex −$709K

Shares (diluted)

5Y −3.4%10Y +12.3%YoY +3.1%
116.5M TTM123.2M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR −1.2%10Y n/mYoY +544.6%
$162.3M TTM$126.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full CORT financials →

About Corcept Therapeutics#

Data provided bySource: Twelve Data

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders. Its commercial portfolio is centered on Korlym, an oral therapy used for adults with endogenous Cushing’s syndrome and related hypercortisolism. The company also advances a pipeline of selective cortisol modulators across multiple therapeutic areas, including relacorilant for Cushing’s syndrome and certain cancers, Lifyorli for oncology, and other investigational programs in metabolic disease and amyotrophic lateral sclerosis. Corcept Therapeutics serves the specialized rare-disease and specialty-pharmaceutical markets, where its products and research are aimed at conditions with limited treatment options. The company is headquartered in Redwood City, California.

Redwood City, CA·730 employees·Biotechnology·corcept.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding CORT#

19 of the 193 ETFs ChartRow carries live hold CORT. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
VIOOVanguard S&P Small-Cap 600 ETF0.6%
IJRiShares Core S&P Small-Cap ETF0.4%
IWPiShares Russell Mid-Cap Growth ETF0.2%
VBKVanguard Small-Cap Growth ETF0.2%
VHTVanguard Health Care ETF0.2%
VXFVanguard Extended Market ETF0.1%
VBVanguard Small-Cap ETF0.1%
IWRiShares Russell Midcap ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%